Allogeneic Hemopoietic Cell Transplantation as a Paradigm for Cellular Immunotherapy

2.

Bazarbachi

A

,

Labopin

M

,

Moukalled

N

,

Kröger

N

,

Rautenberg

C

,

Schetelig

J

, et al.

Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study

.

Clin Cancer Res

.

2024

;

30

(

9

):

1778

–

87

.

3.

Nagler

A

,

Labopin

M

,

Salmenniemi

U

,

Wu

D

,

Blaise

D

,

Rambaldi

A

, et al.

Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT

.

Bone Marrow Transplant

.

2024

;

20

(

10

):

024

–

02379

.

4.

Penack

O

,

Abouqateb

M

,

Peczynski

C

,

Boreland

W

,

Gülbas

Z

,

Gedde-Dahl

T

, et al.

PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation

.

Blood Cancer J

.

2024

;

14

(

1

):

45

.

5.

Kyriakou

C

,

Boumendil

A

,

Finel

H

,

Niederwieser

D

,

Andersen

NS

,

Blaise

D

, et al.

The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation lymphoma working party

.

Biol Blood Marrow Transplant

.

2019

;

25

(

1

):

86

–

93

.

6.

McLornan

D

,

Eikema

DJ

,

Czerw

T

,

Kröger

N

,

Koster

L

,

Reinhardt

HC

, et al.

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

.

Bone Marrow Transplant

.

2021

;

56

(

9

):

2160

–

72

.

7.

Bacigalupo

A

,

Ballen

K

,

Rizzo

D

,

Giralt

S

,

Lazarus

H

,

Ho

V

, et al.

Defining the intensity of conditioning regimens: working definitions

.

Biol Blood Marrow Transplant

.

2009

;

15

(

12

):

1628

–

33

.

8.

Gratwohl

A

,

Pasquini

MC

,

Aljurf

M

,

Atsuta

Y

,

Baldomero

H

,

Foeken

L

, et al.

One million haemopoietic stem-cell transplants: a retrospective observational study

.

Lancet Haematol

.

2015

;

2

(

3

):

e91

–

100

.

9.

Passweg

JR

,

Baldomero

H

,

Ciceri

F

,

Corbacioglu

S

,

de la Cámara

R

,

Dolstra

H

, et al.

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey

.

Bone Marrow Transplant

.

2023

;

58

(

6

):

647

–

58

.

10.

Sorror

ML

,

Sandmaier

BM

,

Storer

BE

,

Franke

GN

,

Laport

GG

,

Chauncey

TR

, et al.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

.

JAMA

.

2011

;

306

(

17

):

1874

–

83

.

11.

Kornblit

B

,

Maloney

DG

,

Storb

R

,

Storek

J

,

Hari

P

,

Vucinic

V

, et al.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial

.

Biol Blood Marrow Transplant

.

2013

;

19

(

9

):

1340

–

7

.

12.

Shouval

R

,

Fein

JA

,

Cho

C

,

Avecilla

ST

,

Ruiz

J

,

Tomas

AA

, et al.

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

.

Blood Adv

.

2022

;

6

(

5

):

1525

–

35

.

13.

Scott

BL

,

Pasquini

MC

,

Logan

BR

,

Wu

J

,

Devine

SM

,

Porter

DL

, et al.

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

.

J Clin Oncol

.

2017

;

35

(

11

):

1154

–

61

.

14.

Kroger

N

,

Iacobelli

S

,

Franke

GN

,

Platzbecker

U

,

Uddin

R

,

Hübel

K

, et al.

Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)

.

J Clin Oncol

.

2017

;

35

(

19

):

2157

–

64

.

15.

Danylesko

I

,

Shimoni

A

,

Nagler

A

.

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

.

Bone Marrow Transplant

.

2012

;

47

(

1

):

5

–

14

.

16.

Shimoni

A

,

Labopin

M

,

Savani

B

,

Hamladji

RM

,

Beelen

D

,

Mufti

G

, et al.

Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia working party of European society for blood and marrow transplantation

.

Biol Blood Marrow Transplant

.

2018

;

24

(

4

):

751

–

7

.

17.

Beelen

DW

,

Trenschel

R

,

Stelljes

M

,

Groth

C

,

Masszi

T

,

Reményi

P

, et al.

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

.

Lancet Haematol

.

2020

;

7

(

1

):

e28

–

39

.

18.

Shimoni

A

,

Robin

M

,

Iacobelli

S

,

Beelen

D

,

Mufti

GJ

,

Ciceri

F

, et al.

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

.

Br J Haematol

.

2021

;

195

(

3

):

417

–

28

.

19.

Giebel

S

,

Labopin

M

,

Schroeder

T

,

Swoboda

R

,

Maertens

J

,

Bourhis

JH

, et al.

Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Am J Hematol

.

2023

;

98

(

4

):

580

–

7

.

20.

Hirschbuhl

K

,

Labopin

M

,

Polge

E

,

Blaise

D

,

Bourhis

JH

,

Socié

G

, et al.

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT

.

Bone Marrow Transplant

.

2023

;

58

(

8

):

874

–

80

.

21.

Schmid

C

,

Schleuning

M

,

Ledderose

G

,

Tischer

J

,

Kolb

HJ

.

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

.

J Clin Oncol

.

2005

;

23

(

24

):

5675

–

87

.

22.

Schneidawind

D

,

Federmann

B

,

Faul

C

,

Vogel

W

,

Kanz

L

,

Bethge

WA

.

Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia

.

Ann Hematol

.

2013

;

92

(

10

):

1389

–

95

.

23.

Steckel

NK

,

Groth

C

,

Mikesch

JH

,

Trenschel

R

,

Ottinger

H

,

Kordelas

L

, et al.

High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia

.

Br J Haematol

.

2018

;

180

(

6

):

840

–

53

.

24.

Owattanapanich

W

,

Ungprasert

P

,

Wais

V

,

Kungwankiattichai

S

,

Bunjes

D

,

Kuchenbauer

F

.

FLAMSA-RIC for stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndromes: a systematic review and meta-analysis

.

J Clin Med

.

2019

;

8

(

9

):

1437

.

25.

Craddock

C

,

Jackson

A

,

Loke

J

,

Siddique

S

,

Hodgkinson

A

,

Mason

J

, et al.

Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia

.

J Clin Oncol

.

2021

;

39

(

7

):

768

–

78

.

26.

Stelljes

M

,

Middeke

JM

,

Bug

G

,

Wagner-Drouet

EM

,

Müller

LP

,

Schmid

C

, et al.

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

.

Lancet Haematol

.

2024

;

11

(

5

):

e324

–

35

.

27.

Schulz

F

,

Jäger

P

,

Tischer

J

,

Fraccaroli

A

,

Bug

G

,

Hausmann

A

, et al.

Smart conditioning with venetoclax-enhanced sequential FLAMSA + RIC in patients with high-risk myeloid malignancies

.

Cancers

.

2024

;

16

(

3

):

532

.

28.

Sloas

C

,

Gill

S

,

Klichinsky

M

.

Engineered CAR-macrophages as adoptive immunotherapies for solid tumors

.

Front Immunol

.

2021

;

12

:

783305

.

29.

Pan

K

,

Farrukh

H

,

Chittepu

VCSR

,

Xu

H

,

Pan

CX

,

Zhu

Z

.

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

.

J Exp Clin Cancer Res

.

2022

;

41

(

1

):

119

.

30.

Liu

E

,

Marin

D

,

Banerjee

P

,

Macapinlac

HA

,

Thompson

P

,

Basar

R

, et al.

Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors

.

N Engl J Med

.

2020

;

382

(

6

):

545

–

53

.

31.

Hu

Y

,

Zhang

M

,

Yang

T

,

Mo

Z

,

Wei

G

,

Jing

R

, et al.

Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis

.

N Engl J Med

.

2024

;

390

(

16

):

1467

–

80

.

32.

Han

L

,

Zhao

R

,

Yang

J

,

Zu

Y

,

Liu

Y

,

Zhou

J

, et al.

Case Report: successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph+ B cell acute lymphoblastic leukemia

.

Front Immunol

.

2022

;

13

.

33.

Patterson

MT

,

Khan

SM

,

Nunes

NS

,

Fletcher

RE

,

Bian

J

,

Hadjis

AD

, et al.

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects

.

Blood

.

2023

;

141

(

6

):

659

–

72

.

34.

Saha

A

,

Hyzy

S

,

Lamothe

T

,

Hammond

K

,

Clark

N

,

Lanieri

L

, et al.

A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice

.

Blood

.

2022

;

139

(

11

):

1743

–

59

.

35.

Czechowicz

A

,

Palchaudhuri

R

,

Scheck

A

,

Hu

Y

,

Hoggatt

J

,

Saez

B

, et al.

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

.

Nat Commun

.

2019

;

10

(

1

):

617

.

36.

Breda

L

,

Papp

TE

,

Triebwasser

MP

,

Yadegari

A

,

Fedorky

MT

,

Tanaka

N

, et al.

In vivo hematopoietic stem cell modification by mRNA delivery

.

Science

.

2023

;

381

(

6656

):

436

–

43

.

37.

Gragert

L

,

Eapen

M

,

Williams

E

,

Freeman

J

,

Spellman

S

,

Baitty

R

, et al.

HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry

.

N Engl J Med

.

2014

;

371

(

4

):

339

–

48

.

38.

Buck

K

,

Wadsworth

K

,

Setterholm

M

,

Maiers

M

,

Confer

D

,

Hartzman

R

, et al.

High-resolution match rate of 7/8 and 9/10 or better for the Be the match unrelated donor registry

.

Biol Blood Marrow Transplant

.

2016

;

22

(

4

):

759

–

63

.

39.

Kollman

C

,

Spellman

SR

,

Zhang

MJ

,

Hassebroek

A

,

Anasetti

C

,

Antin

JH

, et al.

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy

.

Blood

.

2016

;

127

(

2

):

260

–

7

.

40.

Fleischhauer

K

,

Beelen

DW

.

HLA mismatching as a strategy to reduce relapse after alternative donor transplantation

.

Semin Hematol

.

2016

;

53

(

2

):

57

–

64

.

41.

Fleischhauer

K

,

Shaw

BE

.

HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities

.

Blood

.

2017

;

130

(

9

):

1089

–

96

.

42.

Ruggeri

A

,

De Wreede

LC

,

Müller

CR

,

Crivello

P

,

Bonneville

EF

,

Petersdorf

EW

, et al.

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

.

Haematologica

.

2023

;

108

(

2

):

645

–

52

.

43.

Petersdorf

EW

,

Stevenson

P

,

Bengtsson

M

,

De Santis

D

,

Dubois

V

,

Gooley

T

, et al.

HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation

.

Blood

.

2020

;

136

(

3

):

362

–

9

.

44.

Fuchs

EJ

,

McCurdy

SR

,

Solomon

SR

,

Wang

T

,

Herr

MM

,

Modi

D

, et al.

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

.

Blood

.

2022

;

139

(

10

):

1452

–

68

.

45.

Petersdorf

EW

,

Gooley

T

,

Volt

F

,

Kenzey

C

,

Madrigal

A

,

McKallor

C

, et al.

Use of the HLA-B leader to optimize cord blood transplantation

.

Haematologica

.

2021

;

106

(

12

):

3107

–

14

.

46.

Kröger

N

,

Zabelina

T

,

de Wreede

L

,

Berger

J

,

Alchalby

H

,

van Biezen

A

, et al.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings

.

Leukemia

.

2013

;

27

(

3

):

604

–

9

.

47.

Guru Murthy

GS

,

Kim

S

,

Hu

ZH

,

Estrada-Merly

N

,

Abid

MB

,

Aljurf

M

, et al.

Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors

.

JAMA Oncol

.

2022

;

8

(

3

):

404

–

11

.

48.

Canaani

J

,

Savani

BN

,

Labopin

M

,

Huang

XJ

,

Ciceri

F

,

Arcese

W

, et al.

Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation

.

Am J Hematol

.

2018

;

93

(

2

):

246

–

53

.

49.

Ljungman

P

,

Brand

R

,

Hoek

J

,

de la Camara

R

,

Cordonnier

C

,

Einsele

H

, et al.

Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation

.

Clin Infect Dis

.

2014

;

59

(

4

):

473

–

81

.

50.

Kalra

A

,

Williamson

T

,

Daly

A

,

Savoie

ML

,

Stewart

DA

,

Khan

F

, et al.

Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation

.

Biol Blood Marrow Transplant

.

2016

;

22

(

9

):

1654

–

63

.

51.

Shaw

BE

,

Mayor

NP

,

Szydlo

RM

,

Bultitude

WP

,

Anthias

C

,

Kirkland

K

, et al.

Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants

.

Bone Marrow Transplant

.

2017

;

52

(

5

):

717

–

25

.

52.

Shaw

BE

,

Logan

BR

,

Spellman

SR

,

Marsh

SGE

,

Robinson

J

,

Pidala

J

, et al.

Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most

.

Biol Blood Marrow Transplant

.

2018

;

24

(

5

):

1049

–

56

.

53.

Wachsmuth

LP

,

Patterson

MT

,

Eckhaus

MA

,

Venzon

DJ

,

Gress

RE

,

Kanakry

CG

.

Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression

.

J Clin Investig

.

2019

;

129

(

6

):

2357

–

73

.

54.

Fletcher

RE

,

Nunes

NS

,

Patterson

MT

,

Vinod

N

,

Khan

SM

,

Mendu

SK

, et al.

Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs

.

Blood Adv

.

2023

;

7

(

7

):

1117

–

29

.

55.

Reisner

Y

,

Kapoor

N

,

Kirkpatrick

D

,

Pollack

MS

,

Dupont

B

,

Good

RA

, et al.

Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells

.

Lancet

.

1981

;

2

(

8242

):

327

–

31

.

56.

Bethge

WA

,

Eyrich

M

,

Mielke

S

,

Meisel

R

,

Niederwieser

D

,

Schlegel

PG

, et al.

Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

.

Bone Marrow Transplant

.

2022

;

57

(

3

):

423

–

30

.

57.

Schumm

M

,

Lang

P

,

Taylor

G

,

Kuçi

S

,

Klingebiel

T

,

Bühring

HJ

, et al.

Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device

.

J Hematother

.

1999

;

8

(

2

):

209

–

18

.

58.

Federmann

B

,

Bornhauser

M

,

Meisner

C

,

Kordelas

L

,

Beelen

DW

,

Stuhler

G

, et al.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study

.

Haematologica

.

2012

;

97

(

10

):

1523

–

31

.

59.

Schumm

M

,

Lang

P

,

Bethge

W

,

Faul

C

,

Feuchtinger

T

,

Pfeiffer

M

, et al.

Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device

.

Cytotherapy

.

2013

;

15

(

10

):

1253

–

8

.

60.

Bleakley

M

,

Sehgal

A

,

Seropian

S

,

Biernacki

MA

,

Krakow

EF

,

Dahlberg

A

, et al.

Naive T-cell depletion to prevent chronic graft-versus-host disease

.

J Clin Oncol

.

2022

;

40

(

11

):

1174

–

85

.

61.

Bolanos-Meade

J

,

Hamadani

M

,

Wu

J

,

Al Malki

MM

,

Martens

MJ

,

Runaas

L

, et al.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

–

48

.

62.

Battipaglia

G

,

Labopin

M

,

Blaise

D

,

Diez-Martin

JL

,

Bazarbachi

A

,

Vitek

A

, et al.

Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone in acute myelogenous leukemia: a retrospective study on behalf of the acute leukemia working party of the European society for blood and marrow transplantation

.

Transplant Cell Ther

.

2022

;

28

(

9

):

587 e1

–

7

.

63.

El-Cheikh

J

,

Devillier

R

,

Dulery

R

,

Massoud

R

,

Al Chami

F

,

Ghaoui

N

, et al.

Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation

.

Clin Lymphoma Myeloma Leuk

.

2020

;

20

(

9

):

617

–

23

.

64.

Storb

R

,

Deeg

HJ

,

Farewell

V

,

Doney

K

,

Appelbaum

F

,

Beatty

P

, et al.

Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease

.

Blood

.

1986

;

68

(

1

):

119

–

25

.

65.

Ratanatharathorn

V

,

Nash

RA

,

Przepiorka

D

,

Devine

SM

,

Klein

JL

,

Weisdorf

D

, et al.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation

.

Blood

.

1998

;

92

(

7

):

2303

–

14

.

66.

Nash

RA

,

Antin

JH

,

Karanes

C

,

Fay

JW

,

Avalos

BR

,

Yeager

AM

, et al.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

.

Blood

.

2000

;

96

(

6

):

2062

–

8

.

67.

Bolanos-Meade

J

,

Reshef

R

,

Fraser

R

,

Fei

M

,

Abhyankar

S

,

Al-Kadhimi

Z

, et al.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

.

Lancet Haematol

.

2019

;

6

(

3

):

e132

–

43

.

68.

Bacigalupo

A

,

Oneto

R

,

Lamparelli

T

,

Gualandi

F

,

Bregante

S

,

Raiola

AM

, et al.

Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG)

.

Bone Marrow Transplant

.

2001

;

28

(

12

):

1093

–

6

.

69.

Walker

I

,

Panzarella

T

,

Couban

S

,

Couture

F

,

Devins

G

,

Elemary

M

, et al.

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

.

Lancet Oncol

.

2016

;

17

(

2

):

164

–

73

.

70.

Finke

J

,

Schmoor

C

,

Bethge

WA

,

Ottinger

H

,

Stelljes

M

,

Volin

L

, et al.

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial

.

Lancet Haematol

.

2017

;

4

(

6

):

e293

–

301

.

71.

Soiffer

RJ

,

Kim

HT

,

McGuirk

J

,

Horwitz

ME

,

Johnston

L

,

Patnaik

MM

, et al.

Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation

.

J Clin Oncol

.

2017

;

35

(

36

):

4003

–

11

.

72.

Kroger

N

,

Solano

C

,

Wolschke

C

,

Bandini

G

,

Patriarca

F

,

Pini

M

, et al.

Antilymphocyte globulin for prevention of chronic graft-versus-host disease

.

N Engl J Med

.

2016

;

374

(

1

):

43

–

53

.

73.

Chang

YJ

,

Wu

DP

,

Lai

YR

,

Liu

QF

,

Sun

YQ

,

Hu

J

, et al.

Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study

.

J Clin Oncol

.

2020

;

38

(

29

):

3367

–

76

.

74.

Cho

BS

,

Min

GJ

,

Park

SS

,

Yoon

SY

,

Park

S

,

Jeon

YW

, et al.

Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor

.

Am J Hematol

.

2021

;

96

(

11

):

1441

–

9

.

75.

Bonifazi

F

,

Solano

C

,

Wolschke

C

,

Sessa

M

,

Patriarca

F

,

Zallio

F

, et al.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study

.

Lancet Haematol

.

2019

;

6

(

2

):

e89

–

99

.

76.

Binkert

L

,

Medinger

M

,

Halter

JP

,

Heim

D

,

Gerull

S

,

Holbro

A

, et al.

Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation

.

Bone Marrow Transplant

.

2015

;

50

(

10

):

1331

–

6

.

77.

Hoeg

RT

,

Moroz

A

,

Gandhi

A

,

Muffly

L

,

Shiraz

P

,

Oliai

C

, et al.

Orca-T results in high gvhd-free and relapse-free survival following myeloablative conditioning for hematological malignancies: results of a single center phase 2 and a multicenter phase 1b study

.

Blood

.

2021

;

138

(

Suppl 1

):

98

.

78.

MacMillan

ML

,

Hippen

KL

,

McKenna

DH

,

Kadidlo

D

,

Sumstad

D

,

DeFor

TE

, et al.

First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings

.

Blood Adv

.

2021

;

5

(

5

):

1425

–

36

.

79.

Rashidi

A

,

Ebadi

M

,

Rehman

TU

,

Elhusseini

H

,

Kazadi

D

,

Halaweish

H

, et al.

Potential of fecal microbiota transplantation to prevent acute GVHD: analysis from a phase II trial

.

Clin Cancer Res

.

2023

;

29

(

23

):

4920

–

9

.

80.

DeFilipp

Z

,

Damania

AV

,

Kim

HT

,

Chang

CC

,

El-Jawahri

A

,

McAfee

SL

, et al.

Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract

.

Blood Adv

.

2024

;

8

(

9

):

2074

–

84

.

81.

Kean

LS

,

Burns

LJ

,

Kou

TD

,

Kapikian

R

,

Lozenski

K

,

Langston

A

, et al.

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation

.

Blood

.

2024

;

144

(

17

):

1834

–

45

.

82.

Chen

Y-B

,

Saad

A

,

Farhan

SY

,

Lekakis

LJ

,

Schiller

GJ

,

Yared

JA

, et al.

RGI-2001 infusion for prevention of acute gvhd after allogeneic hematopoietic cell transplantation

.

Blood

.

2022

;

140

(

Suppl 1

):

1877

–

8

.

83.

Zhang

X

,

Zhao

X

,

Chen

S

,

Hao

M

,

Zhang

L

,

Gong

M

, et al.

Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients

.

Bone Marrow Transplant

.

2024

;

59

(

7

):

997

–

1005

.

84.

Abboud

R

,

Schroeder

MA

,

Rettig

MP

,

Gao

F

,

Ritchey

JK

,

Abboud

CN

, et al.

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome with T-cell replete peripheral blood haploidentical transplantation

.

Blood

.

2023

;

142

(

Suppl 1

):

651

.

85.

Holtan

SG

.

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

.

Blood

.

2023

;

142

(

Supplement 1

):

4925

.

86.

Waller

EK

,

Horwitz

M

,

Anand

S

,

Tey

SK

,

Berger

M

,

Preiss

R

, et al.

MODULAATE (Part 1): an open-label, dose-finding phase 2 evaluation of alpha-1 antitrypsin for the prevention of graft-versus-host disease in patients receiving hematopoietic cell transplantation

.

Transplant Cell Ther

.

2024

;

30

(

2Suppl

):

S261

.

87.

Sandmaier

BM

,

Kornblit

B

,

Storer

BE

,

Olesen

G

,

Maris

MB

,

Langston

AA

, et al.

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2019

;

6

(

8

):

e409

–

18

.

88.

Zeiser

R

,

Polverelli

N

,

Ram

R

,

Hashmi

SK

,

Chakraverty

R

,

Middeke

JM

, et al.

Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease

.

N Engl J Med

.

2021

;

385

(

3

):

228

–

38

.

89.

Zeiser

R

,

von Bubnoff

N

,

Butler

J

,

Mohty

M

,

Niederwieser

D

,

Or

R

, et al.

Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease

.

N Engl J Med

.

2020

;

382

(

19

):

1800

–

10

.

90.

Abedin

S

,

Rashid

N

,

Schroeder

M

,

Romee

R

,

Nauffal

M

,

Alhaj Moustafa

M

, et al.

Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease: a real-world outcomes analysis

.

Br J Haematol

.

2021

;

195

(

3

):

429

–

32

.

91.

Magenau

JM

,

Goldstein

SC

,

Peltier

D

,

Soiffer

RJ

,

Braun

T

,

Pawarode

A

, et al.

α(1)-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease

.

Blood

.

2018

;

131

(

12

):

1372

–

9

.

92.

Abedin

S

,

Hamadani

M

,

Holtan

SG

,

Schiller

GJ

,

Gallogly

M

,

Waller

EK

, et al.

Neihulizumab (ALTB-168) in patients with steroid-refractory acute graft-versus-host-disease (SR-aGVHD) or treatment-refractory acute graft-versus-host-disease (TR-aGVHD)

.

Blood

.

2022

;

140

(

Suppl 1

):

10495

–

7

.

93.

Dimitriadou

V

,

Chabot-Roy

G

,

Audiger

C

,

Banu

I

,

Delisle

JS

,

Lesage

S

.

P3.05: apraglutide decreases severity of intestinal damage from acute gastrointestinal graft versus host disease (GI-GvHD) following allogeneic transplantation without impacting engraftment

.

Transplantation

.

2022

;

106

(

9S

):

S520

–

1

.

94.

Chen

YB

,

Mohty

M

,

Zeiser

R

,

Teshima

T

,

Jamy

O

,

Maertens

J

, et al.

Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

.

Nat Med

.

2024

;

30

(

8

):

2277

–

87

.

95.

Holtan

SG

,

Hoeschen

A

,

Cao

Q

,

Ustun

C

,

Betts

BC

,

Jurdi

NE

, et al.

Phase II, open-label clinical trial of urinary-derived human chorionic gonadotropin/epidermal growth factor for life-threatening acute graft-versus-host disease

.

Transplant Cell Ther

.

2023

;

29

(

8

):

509.e1

–

8

.

96.

Pidala

J

,

Walton

K

,

Elmariah

H

,

Kim

J

,

Mishra

A

,

Bejanyan

N

, et al.

Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: preclinical and phase I trial results

.

Clin Cancer Res

.

2021

;

27

(

10

):

2712

–

22

.

97.

Ponce

DM

,

Alousi

AM

,

Nakamura

R

,

Slingerland

J

,

Calafiore

M

,

Sandhu

KS

, et al.

A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

.

Blood

.

2023

;

141

(

12

):

1389

–

401

.

98.

Rodríguez-Gil

A

,

Escamilla-Gómez

V

,

Nufer

M

,

Andújar-Sánchez

F

,

Lopes-Ramos

T

,

Bejarano-García

JA

, et al.

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib

.

Sci Rep

.

2022

;

12

(

1

):

8348

.

99.

Li

Y-R

,

Zeng

S

,

Dunn

ZS

,

Zhou

Y

,

Li

Z

,

Yu

J

, et al.

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers

.

iScience

.

2022

;

25

(

9

):

104859

.

100.

Kadri

N

,

Amu

S

,

Iacobaeus

E

,

Boberg

E

,

Le Blanc

K

.

Current perspectives on mesenchymal stromal cell therapy for graft versus host disease

.

Cell Mol Immunol

.

2023

;

20

(

6

):

613

–

25

.

101.

Akahoshi

Y

,

Spyrou

N

,

Weber

D

,

Aguayo-Hiraldo

P

,

Ayuk

F

,

Chanswangphuwana

C

, et al.

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

.

Blood

.

2024

;

144

(

9

):

1010

–

21

.

102.

Miklos

D

,

Cutler

CS

,

Arora

M

,

Waller

EK

,

Jagasia

M

,

Pusic

I

, et al.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

.

Blood

.

2017

;

130

(

21

):

2243

–

50

.

103.

Cutler

C

,

Lee

SJ

,

Arai

S

,

Rotta

M

,

Zoghi

B

,

Lazaryan

A

, et al.

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

.

Blood

.

2021

;

138

(

22

):

2278

–

89

.

104.

Wolff

D

,

Cutler

C

,

Lee

SJ

,

Pusic

I

,

Bittencourt

H

,

White

J

, et al.

Axatilimab in recurrent or refractory chronic graft-versus-host disease

.

N Engl J Med

.

2024

;

391

(

11

):

1002

–

14

.

105.

Zeiser

R

.

Novel approaches to the treatment of chronic graft-versus-host disease

.

J Clin Oncol

.

2023

;

41

(

10

):

1820

–

4

.

106.

Bader

P

,

Kreyenberg

H

,

von Stackelberg

A

,

Eckert

C

,

Salzmann-Manrique

E

,

Meisel

R

, et al.

Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial

.

J Clin Oncol

.

2015

;

33

(

11

):

1275

–

84

.

107.

Balduzzi

A

,

Di Maio

L

,

Silvestri

D

,

Songia

S

,

Bonanomi

S

,

Rovelli

A

, et al.

Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention

.

Br J Haematol

.

2014

;

164

(

3

):

396

–

408

.

108.

Ossenkoppele

G

,

Schuurhuis

GJ

.

MRD in AML: does it already guide therapy decision-making

.

Hematol Am Soc Hematol Educ Program

.

2016

;

2016

(

1

):

356

–

65

.

109.

Dohner

H

.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

–

77

.

110.

Heuser

M

,

Freeman

SD

,

Ossenkoppele

GJ

,

Buccisano

F

,

Hourigan

CS

,

Ngai

LL

, et al.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

.

Blood

.

2021

;

138

(

26

):

2753

–

67

.

111.

Conter

V

,

Bartram

CR

,

Valsecchi

MG

,

Schrauder

A

,

Panzer-Grümayer

R

,

Möricke

A

, et al.

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

.

Blood

.

2010

;

115

(

16

):

3206

–

14

.

112.

Gokbuget

N

,

Kneba

M

,

Raff

T

,

Trautmann

H

,

Bartram

CR

,

Arnold

R

, et al.

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

.

Blood

.

2012

;

120

(

9

):

1868

–

76

.

113.

Bassan

R

,

Spinelli

O

.

Minimal residual disease monitoring in adult ALL to determine therapy

.

Curr Hematol Malig Rep

.

2015

;

10

(

2

):

86

–

95

.

114.

Balsat

M

,

Renneville

A

,

Thomas

X

,

de Botton

S

,

Caillot

D

,

Marceau

A

, et al.

Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French association group

.

J Clin Oncol

.

2017

;

35

(

2

):

185

–

93

.

115.

Jongen-Lavrencic

M

,

Grob

T

,

Hanekamp

D

,

Kavelaars

FG

,

Al Hinai

A

,

Zeilemaker

A

, et al.

Molecular minimal residual disease in acute myeloid leukemia

.

N Engl J Med

.

2018

;

378

(

13

):

1189

–

99

.

116.

Buckley

SA

,

Wood

BL

,

Othus

M

,

Hourigan

CS

,

Ustun

C

,

Linden

MA

, et al.

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

.

Haematologica

.

2017

;

102

(

5

):

865

–

73

.

117.

Walter

RB

,

Gyurkocza

B

,

Storer

BE

,

Godwin

CD

,

Pagel

JM

,

Buckley

SA

, et al.

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

.

Leukemia

.

2015

;

29

(

1

):

137

–

44

.

118.

Araki

D

,

Wood

BL

,

Othus

M

,

Radich

JP

,

Halpern

AB

,

Zhou

Y

, et al.

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission

.

J Clin Oncol

.

2016

;

34

(

4

):

329

–

36

.

119.

Terwijn

M

,

Zeijlemaker

W

,

Kelder

A

,

Rutten

AP

,

Snel

AN

,

Scholten

WJ

, et al.

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

.

PLoS One

.

2014

;

9

(

9

):

e107587

.

120.

Zeijlemaker

W

,

Kelder

A

,

Oussoren-Brockhoff

YJM

,

Scholten

WJ

,

Snel

AN

,

Veldhuizen

D

, et al.

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia

.

Leukemia

.

2016

;

30

(

2

):

439

–

46

.

121.

Waterhouse

M

,

Pennisi

S

,

Pfeifer

D

,

Scherer

F

,

Zeiser

R

,

Duyster

J

, et al.

Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation

.

Cancers

.

2022

;

14

(

14

):

3307

.

122.

Kolb

HJ

,

Mittermüller

J

,

Clemm

C

,

Holler

E

,

Ledderose

G

,

Brehm

G

, et al.

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

.

Blood

.

1990

;

76

(

12

):

2462

–

5

.

123.

Flutter

B

,

Edwards

N

,

Fallah-Arani

F

,

Henderson

S

,

Chai

JG

,

Sivakumaran

S

, et al.

Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation

.

J Clin Investig

.

2010

;

120

(

11

):

3855

–

68

.

124.

Saha

A

,

O’Connor

RS

,

Thangavelu

G

,

Lovitch

SB

,

Dandamudi

DB

,

Wilson

CB

, et al.

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality

.

J Clin Investig

.

2016

;

126

(

7

):

2642

–

60

.

125.

Davids

MS

,

Kim

HT

,

Bachireddy

P

,

Costello

C

,

Liguori

R

,

Savell

A

, et al.

Ipilimumab for patients with relapse after allogeneic transplantation

.

N Engl J Med

.

2016

;

375

(

2

):

143

–

53

.

126.

Herbaux

C

,

Gauthier

J

,

Brice

P

,

Drumez

E

,

Ysebaert

L

,

Doyen

H

, et al.

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

.

Blood

.

2017

;

129

(

18

):

2471

–

8

.

127.

Davids

MS

,

Kim

HT

,

Costello

C

,

Herrera

AF

,

Locke

FL

,

Maegawa

RO

, et al.

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

.

Blood

.

2020

;

135

(

24

):

2182

–

91

.

128.

Henden

AS

,

Varelias

A

,

Leach

J

,

Sturgeon

E

,

Avery

J

,

Kelly

J

, et al.

Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation

.

Blood Adv

.

2019

;

3

(

20

):

3013

–

9

.

129.

Bailey

C

,

Wei

Y

,

Yan

J

,

Huang

D

,

Zhang

P

,

Qi

C

, et al.

Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease

.

Cell Rep Med

.

2023

;

4

(

11

):

101236

.

130.

Ciceri

F

,

Bonini

C

,

Stanghellini

MTL

,

Bondanza

A

,

Traversari

C

,

Salomoni

M

, et al.

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study

.

Lancet Oncol

.

2009

;

10

(

5

):

489

–

500

.

131.

Song

Y

,

Zhu

Y

,

Hu

B

,

Liu

Y

,

Lin

D

,

Jin

Z

, et al.

Donor γδT cells promote GVL effect and mitigate aGVHD in allogeneic hematopoietic stem cell transplantation

.

Front Immunol

.

2020

;

11

:

558143

.

132.

Schlegel

P

,

Lang

AM

,

Matela

M

,

Horrer

A

,

Schilling

A

,

Jöchner

A

, et al.

Ex vivo expansion of autologous, donor-derived NK-γδT-and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity

.

Bone Marrow Transplant

.

2019

;

54

(

Suppl 2

):

727

–

32

.

133.

Phely

L

,

Hensen

L

,

Faul

C

,

Ruff

CA

,

Schneider

D

,

Bethge

WA

, et al.

Allogeneic CD19/CD22 CAR T-cell therapy for B-cell acute lymphoblastic leukemia

.

JAMA Oncol

.

2024

;

10

(

6

):

821

–

4

.

134.

Mathew

NR

,

Baumgartner

F

,

Braun

L

,

O’Sullivan

D

,

Thomas

S

,

Waterhouse

M

, et al.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

.

Nat Med

.

2018

;

24

(

3

):

282

–

91

.

135.

Burchert

A

,

Bug

G

,

Fritz

LV

,

Finke

J

,

Stelljes

M

,

Röllig

C

, et al.

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3–internal tandem duplication mutation (SORMAIN)

.

J Clin Oncol

.

2020

;

38

(

26

):

2993

–

3002

.

136.

Xuan

L

,

Wang

Y

,

Huang

F

,

Fan

Z

,

Xu

Y

,

Sun

J

, et al.

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

.

Lancet Oncol

.

2020

;

21

(

9

):

1201

–

12

.

137.

Gagelmann

N

,

Wolschke

C

,

Klyuchnikov

E

,

Christopeit

M

,

Ayuk

F

,

Kröger

N

.

TKI maintenance after stem-cell transplantation for FLT3-ITD positive acute myeloid leukemia: a systematic review and meta-analysis

.

Front Immunol

.

2021

;

12

:

630429

.

138.

Metzelder

SK

,

Schroeder

T

,

Finck

A

,

Scholl

S

,

Fey

M

,

Götze

K

, et al.

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

.

Leukemia

.

2012

;

26

(

11

):

2353

–

9

.

139.

Fathi

AT

,

Kim

HT

,

Soiffer

RJ

,

Levis

MJ

,

Li

S

,

Kim

AS

, et al.

Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia

.

Clin Cancer Res

.

2023

;

29

(

11

):

2034

–

42

.

140.

Kantarjian

HM

,

DeAngelo

DJ

,

Stelljes

M

,

Martinelli

G

,

Liedtke

M

,

Stock

W

, et al.

Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia

.

N Engl J Med

.

2016

;

375

(

8

):

740

–

53

.

141.

Ueda

M

,

de Lima

M

,

Caimi

P

,

Tomlinson

B

,

Little

J

,

Creger

R

, et al.

Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant

.

Bone Marrow Transplant

.

2016

;

51

(

9

):

1253

–

5

.

142.

Gaballa

MR

,

Banerjee

P

,

Milton

DR

,

Jiang

X

,

Ganesh

C

,

Khazal

S

, et al.

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

.

Blood

.

2022

;

139

(

12

):

1908

–

19

.

143.

Beer

SA

,

Bethge

W

,

Faul

C

,

Lengerke

C

,

Vogel

W

.

Case report: sequential inotuzumab, blinatumomab, and chemotherapy with concurrent donor lymphocyte infusions induce complete remission in relapsed pre-B acute lymphoblastic leukemia

.

EJHaem

.

2024

;

5

(

3

):

620

–

3

.

144.

Konopleva

M

,

Pollyea

DA

,

Potluri

J

,

Chyla

B

,

Hogdal

L

,

Busman

T

, et al.

Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia

.

Cancer Discov

.

2016

;

6

(

10

):

1106

–

17

.

145.

DiNardo

CD

,

Pratz

K

,

Pullarkat

V

,

Jonas

BA

,

Arellano

M

,

Becker

PS

, et al.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

.

Blood

.

2019

;

133

(

1

):

7

–

17

.

146.

Pollyea

DA

,

Stevens

BM

,

Jones

CL

,

Winters

A

,

Pei

S

,

Minhajuddin

M

, et al.

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

.

Nat Med

.

2018

;

24

(

12

):

1859

–

66

.

147.

Cluzeau

T

,

Sebert

M

,

Loschi

M

,

Ades

L

,

Thepot

S

,

Carre

M

, et al.

Phase I/II clinical trial evaluating azacitidine + venetoclax + donor lymphocyte infusion in post-transplant relapse myelodysplastic syndromes and acute myeloid leukemia: preliminary results of ventograft, a GFM study

.

Blood

.

2023

;

142

(

Suppl 1

):

3246

.

148.

Murdock

HM

,

Ho

VT

,

Garcia

JS

.

Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect

.

Front Immunol

.

2024

;

15

(

1359113

):

1359113

.

149.

Chen

YB

,

Li

S

,

Lane

AA

,

Connolly

C

,

Del Rio

C

,

Valles

B

, et al.

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia

.

Biol Blood Marrow Transplant

.

2014

;

20

(

12

):

2042

–

8

.

150.

Schlenk

RF

,

Weber

D

,

Fiedler

W

,

Salih

HR

,

Wulf

G

,

Salwender

H

, et al.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

.

Blood

.

2019

;

133

(

8

):

840

–

51

.

151.

Sandmaier

BM

,

Khaled

S

,

Oran

B

,

Gammon

G

,

Trone

D

,

Frankfurt

O

.

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

.

Am J Hematol

.

2018

;

93

(

2

):

222

–

31

.

152.

Fathi

AT

,

Kim

HT

,

Soiffer

RJ

,

Levis

MJ

,

Li

S

,

Kim

AS

, et al.

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

.

Blood Adv

.

2022

;

6

(

22

):

5857

–

65

.

153.

Garcia

JS

,

Kim

HT

,

Murdock

HM

,

Cutler

CS

,

Brock

J

,

Gooptu

M

, et al.

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

.

Blood Adv

.

2021

;

5

(

24

):

5536

–

45

.

154.

Mishra

A

,

Tamari

R

,

DeZern

AE

,

Byrne

MT

,

Gooptu

M

,

Chen

YB

, et al.

Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes

.

J Clin Oncol

.

2022

;

40

(

34

):

3985

–

93

.

155.

Bug

G

,

Burchert

A

,

Wagner

EM

,

Kröger

N

,

Berg

T

,

Güller

S

, et al.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

.

Leukemia

.

2017

;

31

(

11

):

2523

–

5

.

156.

Cooperrider

JH

,

Fulton

N

,

Artz

AS

,

Larson

RA

,

Stock

W

,

Kosuri

S

, et al.

Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome

.

Bone Marrow Transplant

.

2020

;

55

(

11

):

2204

–

6

.

157.

Bhatt

VR

,

Wichman

C

,

Bouska

AC

,

Maness

L

,

Al-Kadhimi

ZS

,

Iqbal

J

, et al.

Novel first-in-class drug ONC201 as a post-transplant maintenance for AML and MDS: a phase I trial in progress

.

Blood

.

2022

;

140

(

Suppl 1

):

12918

–

9

.

158.

Maertens

JA

,

Rahav

G

,

Lee

DG

,

Ponce-de-León

A

,

Ramírez Sánchez

IC

,

Klimko

N

, et al.

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

.

Lancet

.

2021

;

397

(

10273

):

499

–

509

.

159.

Tissot

F

,

Agrawal

S

,

Pagano

L

,

Petrikkos

G

,

Groll

AH

,

Skiada

A

, et al.

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

.

Haematologica

.

2017

;

102

(

3

):

433

–

44

.

160.

Cornely

OA

,

Arikan-Akdagli

S

,

Dannaoui

E

,

Groll

AH

,

Lagrou

K

,

Chakrabarti

A

, et al.

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013

.

Clin Microbiol Infect

.

2014

;

20

(

Suppl 3

):

5

–

26

.

161.

White

PL

,

Barnes

RA

,

Springer

J

,

Klingspor

L

,

Cuenca-Estrella

M

,

Morton

CO

, et al.

Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR initiative

.

J Clin Microbiol

.

2015

;

53

(

9

):

2832

–

7

.

162.

Marty

FM

,

Ljungman

P

,

Chemaly

RF

,

Maertens

J

,

Dadwal

SS

,

Duarte

RF

, et al.

Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation

.

N Engl J Med

.

2017

;

377

(

25

):

2433

–

44

.

163.

Ljungman

P

,

de la Camara

R

,

Robin

C

,

Crocchiolo

R

,

Einsele

H

,

Hill

JA

, et al.

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)

.

Lancet Infect Dis

.

2019

;

19

(

8

):

e260

–

72

.

164.

Avery

RK

,

Alain

S

,

Alexander

BD

,

Blumberg

EA

,

Chemaly

RF

,

Cordonnier

C

, et al.

Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial

.

Clin Infect Dis

.

2022

;

75

(

4

):

690

–

701

.

165.

Neuenhahn

M

,

Albrecht

J

,

Odendahl

M

,

Schlott

F

,

Dössinger

G

,

Schiemann

M

, et al.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

.

Leukemia

.

2017

;

31

(

10

):

2161

–

71

.

166.

Obermaier

B

,

Braun

C

,

Hensen

L

,

Ahmad

O

,

Faul

C

,

Lang

P

, et al.

Adenovirus- and cytomegalovirus-specific adoptive T-cell therapy in the context of hematologic cell transplant or HIV infection: a single-center experience

.

Transpl Infect Dis

.

2024

;

26

(

4

):

e14296

.

167.

Feuchtinger

T

,

Lücke

J

,

Hamprecht

K

,

Richard

C

,

Handgretinger

R

,

Schumm

M

, et al.

Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation

.

Br J Haematol

.

2005

;

128

(

4

):

503

–

9

.

168.

Muffly

LS

,

Kocherginsky

M

,

Stock

W

,

Chu

Q

,

Bishop

MR

,

Godley

LA

, et al.

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients

.

Haematologica

.

2014

;

99

(

8

):

1373

–

9

.

169.

Hegde

A

,

Murthy

HS

.

Frailty: the missing piece of the pre-hematopoietic cell transplantation assessment

.

Bone Marrow Transplant

.

2018

;

53

(

1

):

3

–

10

.

170.

Weller

JF

,

Lengerke

C

,

Finke

J

,

Schetelig

J

,

Platzbecker

U

,

Einsele

H

, et al.

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

.

Haematologica

.

2024

;

109

(

2

):

431

–

43

.

171.

Aldoss

I

,

Shan

H

,

Yang

D

,

Clark

MC

,

Al Malki

M

,

Aribi

A

, et al.

Consolidation with first and second allogeneic transplants in adults with relapsed/refractory B-ALL following response to CD19CAR T cell therapy

.

Transplant Cell Ther

.

2024

;

30

(

8

):

788 e1

–

9

.

172.

Fielding

AK

,

Richards

SM

,

Chopra

R

,

Lazarus

HM

,

Litzow

MR

,

Buck

G

, et al.

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

.

Blood

.

2007

;

109

(

3

):

944

–

50

.

173.

Li

Y

,

Li

Y

,

Zhang

M

,

Zhao

H

,

Zhu

M

,

Huang

H

, et al.

Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation

.

Eur J Haematol

.

2024

;

112

(

1

):

94

–

101

.

174.

Htut

M

,

Dhakal

B

,

Cohen

AD

,

Martin

T

,

Berdeja

JG

,

Usmani

SZ

, et al.

Ciltacabtagene autoleucel in patients with prior allogeneic stem cell transplant in the CARTITUDE-1 study

.

Clin Lymphoma Myeloma Leuk

.

2023

;

23

(

12

):

882

–

8

.

175.

Jiang

Y

,

Feng

D

,

Zhu

J

,

Wei

D

,

Zhao

C

,

Liu

H

, et al.

Case report: preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation

.

Front Immunol

.

2024

;

15

:

1381308

.

176.

Cordas Dos Santos

DM

,

Tix

T

,

Shouval

R

,

Gafter-Gvili

A

,

Alberge

JB

,

Cliff

ERS

, et al.

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

.

Nat Med

.

2024

;

30

(

9

):

2667

–

78

.